Game,

In reply to the three "key reasons" that keep your skepticism alive -

1. No revenue from silver coated beads for last 2-3 years - as I have posted previously, no revenue should be anticipated until the silver coated beads demonstrate their "superiority" in clinical trials and the medical market embraces the launch of the POC analyzer that utilizes these silver coated beads. When this happens, Cardiogenics will then be able to successfully commercialize sales of their silver coated beads.

2. "Now the study is with 2 hospitals; what happened here, did the others rescind their agreements to participate? Did the company decide 2 was enough to collect the samples data?" - all we know is that two of the many hospitals affiliated with Wayne State University have enrolled patients in the Beta Site study. The number of hosptials enrolling patients should not be your focus but rather the time line presented by Cardiogenics to recruit the 200 Beta Site study population. Two hospitals or ten is not the issue, completion of the Beta Site Study by mid-November is key!